OSCR Company Profile and Key Details

Oscar Health, Inc. has 223.04 million shares outstanding. The public float is 210.30 million shares, elevated short interest at 29.95% of float. This equals 60.08 million shares. The short ratio is 1.57 days. Institutional investors hold 79.99% of the float. Insiders own 4.03%. Kushner Joshua holds 6.34 million shares, Thrive Partners VII Growth GP, LLC has 6.34 million shares and Blackley Richard Scott has 1.35 million shares. Over the past six months, insider transactions show net selling. They sold 1.22 million shares across 13 transactions.

Short-term trend indicators are bullishly aligned (SMA20 -19.65%, SMA50 -20.99%, SMA200 -23.81%). The stock’s 14-day RSI is 26.04 (weak momentum), while the ATR of 0.81 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -47.44% below its high and over 11.7% above its low. Average 10-day trading volume of 6.88 million shares is below the 3-month average of 10.66 million, indicating normal recent market interest.

Wall Street analysts project EPS growth of 114.55% annually over the next five years. The latest quarter delivered EPS of -$0.54. The next quarter is forecast at -$0.89. Next year's EPS is expected at $71.51. Analyst sentiment is neutral. Analyst rating data shows there are 1 Strong Buy ratings, 0 Buy ratings, 7 Hold ratings, 2 Sell rating and 6 Strong Sell ratings. Price targets range from $25.00 to $10.00. The high target offers 99.84% upside. The low target suggests -20.06% downside. The mean target is $14.75. This offers 17.91% upside. Oscar Health, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by -2.16%. The prior quarter beat by -1.11%. Over the last six quarters, Apple has recorded several small beats. These include 25.0% in August 07, 2024.

Oscar Health, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$21.17. This means the shares are trading below this model’s fair value.

Oscar Health, Inc. (NYSE:OSCR) closed at $12.51 USD, losing -$0.71 (-5.37%) from the previous close of $13.22. The stock is currently mid-range between its 52-week high and low $11.20 and $23.80. With a market capitalization of about $3.20 billion, Oscar Health, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~1.90). Key stats such as the average daily volume over the past year has been around 10.82 million shares, in line with its 52-week average. Headquartered in New York City, NY, Oscar Health, Inc. operates in the Healthcare sector and the Medical - Healthcare Plans industry. Led by CEO Mark Thomas Bertolini, the company employs approximately 2,400 people and listed since March 03, 2021. Oscar Health, Inc. provides health insurance products and services in the United States.

Oscar Health, Inc. trades at a P/E ratio of -13.41, slightly below the S&P 500 average, with a price-to-sales ratio of 0.29 and a price-to-book ratio of 3.2 trading at moderately above to book value. The P/FCF stands at 4.38, also above market averages.

Oscar Health, Inc. (NYSE:OSCR) shares are up 10.79% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Oscar Health, Inc. trading at a premium to the broader market with a P/E of -13.41. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $13.47, suggesting 7.67% upside. Our AI forecast model points to short-term weakness (-7.75% over two weeks), a medium-term fall (-6.16% over three months), and a longer-term gain (103.68% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Oscar Health, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -7.75%, with price expected at $11.54 by February 19, 2026, within a range of $10.70 to $12.44 3-Month Outlook: Projected fall of -6.16%, reaching $11.74 by May 06, 2026, with a range of $10.93 to $12.44. 1-Year Outlook: Projected gain of 103.68%, with price at $25.48 by February 05, 2027, within a range of $22.21 to $32.82.